The purpose of the present review is to focus on the therapeutic potential of HSP inhibitors in the management of patients diagnosed with MPN and to summarize the accumulating evidence of the role of the PD-1/PD-L1 axis in MPN, providing perspective on future opportunities relative to the inhibition of these targets. Here, PDCD1 is linked to myeloproliferative disorder.